MedPath

EO-3021 Demonstrates Effectiveness in CLDN18.2-Expressing Cancer Models

Recent preclinical studies have shown that EO-3021, an antibody-drug conjugate targeting CLDN18.2, exhibits efficacy in models of gastric adenocarcinoma when combined with VEGFR-2 or PD-1 inhibitors.

Claudin 18.2 (CLDN18.2), a protein overexpressed in several types of cancer including gastric, gastroesophageal junction, and pancreatic cancer, has been the focus of recent research. Elevation Oncology Inc. has presented preclinical data highlighting the efficacy of EO-3021, an antibody-drug conjugate (ADC) designed to target CLDN18.2. The research demonstrated that when EO-3021 is used in combination with VEGFR-2 or PD-1 inhibitors, it shows promising results in models of gastric adenocarcinoma. This development could pave the way for new treatment options for patients with CLDN18.2-expressing cancers.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Elevation Oncology Advances ADC Programs Targeting Gastric and GEJ Cancers

Elevation Oncology initiated dosing of EO-3021, a Claudin 18.2 ADC, in combination with ramucirumab or dostarlimab for advanced gastric/GEJ cancer patients.
Additional monotherapy data from the Phase 1 trial of EO-3021 is expected in the first half of 2025, building on promising initial results.

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise

William Blair analyst Andy Hsieh praises Elevation Oncology for its promising cancer therapies, particularly its antibody-drug conjugate expertise targeting Claudin 18.2 and HER3, highlighting a favorable risk-to-reward ratio and significant market potential.

FDA Approves Zolbetuximab for CLDN18.2-Positive Gastric and GEJ Adenocarcinoma

The FDA approved zolbetuximab in combination with chemotherapy for HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma on October 18, 2024.
Approval was based on the SPOTLIGHT and GLOW phase 3 trials, which demonstrated improved progression-free and overall survival with zolbetuximab plus chemotherapy.

FDA Approves Zolbetuximab for CLDN18.2-Positive Gastric and GEJ Adenocarcinoma

The FDA approved zolbetuximab (Vylov) in combination with chemotherapy for first-line treatment of CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma.
The approval was based on the SPOTLIGHT and GLOW trials, which demonstrated improved progression-free survival with zolbetuximab plus chemotherapy.

Advancements in Gastroesophageal Cancer: FLOT Regimens, HER2 Inhibition, and Zolbetuximab

FLOT (docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil) is now the preferred regimen for localized adenocarcinoma, as radiation therapy has not shown improved outcomes.
The FDA approval of zolbetuximab plus chemotherapy marks a significant advancement for Claudin 18.2 (CLDN18.2)-positive gastric/gastroesophageal junction (GEJ) tumors.

Elevation Oncology's EO-3021 Shows Promise in Gastric and GEJ Cancer Treatment

Elevation Oncology's EO-3021 demonstrated a 42.8% confirmed objective response rate (ORR) in Claudin 18.2-enriched gastric and GEJ cancer patients in Phase 1 trials.
Preclinical data presented at ESMO-IO 2024 supports the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors, showing synergistic anti-tumor activity.

FDA Approves Zolbetuximab for Claudin 18.2-Positive Gastric and Gastroesophageal Junction Cancers

The FDA approved zolbetuximab-clzb (Vyloy), a claudin 18.2-targeted antibody, in combination with chemotherapy for first-line treatment of locally advanced or metastatic gastric or GEJ cancer.
The approval was based on the SPOTLIGHT and GLOW phase III trials, which demonstrated statistically significant improvements in progression-free and overall survival.

FDA Grants Fast Track Designation to Elevation Oncology's EO-3021 for Gastric and GEJ Cancers

The FDA has granted Fast Track designation to EO-3021 for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancer expressing Claudin 18.2.
EO-3021, a differentiated antibody-drug conjugate, targets Claudin 18.2, a protein exposed in malignant transformation of gastric epithelial cells.

Elevation Oncology's EO-3021 Shows Promise in Claudin 18.2-Expressing Solid Tumors

EO-3021 demonstrates a 42.8% objective response rate in gastric and GEJ cancer patients with high Claudin 18.2 expression.
The antibody-drug conjugate exhibits a favorable safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy.

Givastomig Demonstrates Anti-Tumor Activity in Gastric Cancer via Targeted T-Cell Activation

I-Mab's givastomig, a Claudin18.2 x 4-1BB bispecific antibody, shows promising anti-tumor activity by selectively activating T cells within CLDN18.2-expressing tumors.
Preclinical studies reveal givastomig's ability to induce localized immune activation, increasing CD8+/Treg cell ratio and eliciting a lasting memory response against tumor rechallenge.

Reference News

[1]
EO-3021 shows efficacy in CLDN18.2-expressing cancer models
bioworld.com · Dec 16, 2024

Claudin 18.2 (CLDN18.2) is overexpressed in certain cancers. Elevation Oncology Inc. presented data on EO-3021, an ADC t...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy